Rosaria Benedetti

TL;DR: WGBS analysis during adaptation of 2i ESCs to serum suggests that deposition ofDNA methylation is largely random, while loss of DNA methylation during reversion to 2i occurs passively, initiating at TET1 binding sites.

TL;DR: The biological features of epigenetic molecules are focused on, analyzing the mechanism(s) of action and their current use in clinical practice, and small molecules that reverse epigenetic inactivation are reviewed.

TL;DR: Several HDACi, alone or in combination with DNA-demethylating agents, chemopreventive, or classical chemotherapeutic drugs, are currently being used in clinical trials for solid and hematological malignancies, and are, thus, promising candidates for cancer therapy.

TL;DR: In prostate cancer, two different types of histone lysine demethylases (KDM), LSD1/KDM1 and JMJD2/kDM4, are coexpressed and colocalize with the androgen receptor as mentioned in this paper.

TL;DR: A key role is identified for c-Myc in TRAIL deregulation and as a biomarker of the anticancer action of HDACi in AML, which could pave the way toward personalized therapies.